Q: What does Abzyme do?
A: We develop recombinant antibodies for research, diagnostic and therapeutic applications for the benefit of our portfolio and that of our customers and partners. Our approach is unique. We use our proprietary eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries for rapid target-directed antibody maturation with affinity selection by FACS single cell sorting to identify and select antibodies with desired attributes.
Q: What services does Abzyme provide?
A: We develop antibodies against targets of your interest using one of our antibody libraries, which include human Fab, human VH, camelid VHH, human ScFv and rabbit mAb. We offer antibody optimization and characterization. We provide custom antibody engineering, including bispecific antibodies, humanizing antibody and antibody-isotype switching.
Q: What is Abzyme’s antibody discovery platform?
A: All of our libraries are yeast based and highly diversified. Our libraries are developed on our patent-pending triple-mode platform consisting of an in vivo antibody maturation mode, affinity selection, a switchable cell surface presentation and secretion mode.
Q: What is the format of Abzyme’s antibody?
A: We offer multiple antibody formats, including human Fab, human IgG, human ScFV, human single domain VH, camelid single domain VHH, rabbit monoclonal antibodies, and Abz2 bispecific antibodies with Fc structure. If we do not have what you need today, we will use our experience in antibody expression libraries to create the tool to suit your needs.
Q: What is the advantage of working with Abzyme?
A: Abzyme is different.
- SPEED: We are the team to accelerate your antibody discovery program. In as little as six weeks, we can deliver antibody candidates that suits the specific characteristics for your testing.
- BESPOKE: Our platform allows real-time crafting of key characteristics:
a. AFFINITY: desired affinity (whether low or high) is modulated in real-time selection
b. EXPRESSION: eukaryotic system to select antibodies that most-likely express well in mammalian cells
c. EPITOPE DIVERSITY: unprecedented diversity of antibody libraries to select antibodies targeting different epitopes
d. DIFFICULT TARGETS: our platform can tackle membrane protein, toxic and non-immunogenic targets
- KNOWLEDGE: We are experts in antibody platform technology and delivering results on projects others could not handle.
- ENTREPRENEURS: We are entrepreneurs who understand the value of time and money. We build lasting relationships centered on win-win business arrangements
Q: What is the timeframe to develop a customized antibody?
A: We will have antibody hits in as little as six weeks.
Q. How much material is needed?
A. To start, we require 100µg of antigen for bio-panning and FACS-sorting. For antibody characterization (e.g. ELISA, SPR, Western blots) we will need another 1mg of material.
Q: How is my project managed?
A: Each project is overseen by a dedicated project manager. This person will help design a work scope based on your unique needs and then act as a technical point of contact as it is executed. Our project managers are each experienced bench scientists and can assist with planning of assays and interpretation of results to conduct each project in a timely fashion.
You will receive regular written updates about the progress of your project. We will interact and communicate with you to keep you informed and as necessary adjust the project to new requirements. Your participation in the process is beneficial to the success of the project.
We are responsive and will work with you on a schedule to accommodate your needs.
Q: What is the deliverable for a project?
A: The typical deliverables include recombinant antibodies as purified proteins, plasmid DNA or gene sequences, as well as project reports with experimental data.
Q: How do I get started?
A: Contact us. We can be reached at: [email protected] We’ll arrange for an introductory discussion and determine the next steps with you.